Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is not right
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 30, 2021 9:03am
151 Views
Post# 33099983

RE:RE:RE:RE:This is not right

RE:RE:RE:RE:This is not right
Stoxxhp wrote:
StockingUp21 wrote: This is what I talking about. 2 minutes later a defense. Are you retail too? Or employee? Institutions can't and don't buy this so how else to get people to buy? Employ pumper on message board?


Yes, I am a retail investor, I own over 27,000 shares. The reason I don't panic in the least, is because I have done enough work and have alloted a sufficient amount of time for the investment to play out. 
If I have concerns or questions, I will inquire with the company, If I accept the answers I'm given then I will maintain my investment, if I'm dissatisfied with anything then I'll make a decision accordingly. What I am not going to do, is get my answers on stockhouse, where emotions take precedence over facts.




Exactly Stoxxhp.
Not sure why people worry about others here.
Focus on the investment and where it's going.

Do companies have people (maybe even their legal team) watching social media?  Sure they might ... but they don't get involved in the conversations.  I once had an investor demand that a CEO fire me as I was apparently giving away too much information ????    Had a coffee with that CEO when he figured out my alias.  I even had a writer contact me once and threaten legal action.

I'm used to the abuse - hahaha !
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities